Trulieve Q4 revenue drops, but loss narrows

Trulieve Cannabis

26/02/2026 11:24

Overview

U.S. cannabis firm's Q4 revenue was $293 mln, down 3%; with a 60% gross margin

Company reported a Q4 net loss of $43 mln, narrower than year ago

Company opened new dispensary in Ohio and received Texas license approval

Outlook

Trulieve prioritizes expanded access and growth initiatives for 2026

Company aims to leverage conditional Texas license for future growth

Result Drivers

RETAIL SALES - 93% of Q4 revenue came from retail sales, contributing to overall revenue stability

CASH FLOW - Generated $59 mln in Q4 cash flow from operations, supporting record annual cash flow

NEW APP AND DISPENSARY - Launched mobile app in Florida and opened new dispensary in Ohio to support growth

Company press release: ID:nPnc3v8mla

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$293 mln
Q4 Adjusted EPS
-$0.02
Q4 EPS
-$0.23
Q4 Adjusted Net Income
-$3 mln
Q4 Net Income
-$43 mln
Q4 Adjusted EBITDA
$105 mln
Q4 Gross Profit
$175 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Trulieve Cannabis Corp is C$19.50, about 122.9% above its February 25 closing price of C$8.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)